Background: Psoriasis is associated with obesity and metabolic syndrome. Metabolic syndrome is associated with visceral fat accumulation. There is no study on the accumulation of visceral fat in patients with psoriasis. Objective: The aim of this study was to compare the visceral fat accumulation in patients with psoriasis and controls. Subjects and Methods: 46 patients with psoriasis and 46 sex- and age-matched control patients were included in this study. The abdominal fat area [visceral fat area (VFA), subcutaneous fat area (SFA) and total fat area (TFA)] at the level of the umbilicus was evaluated by computed tomography. Results: The mean VFA value and VFA/SFA ratio of the psoriasis patients were significantly higher compared with the control patients (123.4 ± 80.3 vs. 81.2 ± 59.8 cm2 and 0.734 ± 0.593 vs. 0.491 ± 0.336; p = 0.005 and p = 0.017, respectively). Fasting blood sugar levels were also found to be significantly higher in psoriasis patients, compared with the control patients (101.8 ± 43.5 vs. 83.4 ± 9.1 mg/dl; p = 0.005). Multiple linear regression analysis indicated that waist-to-hip ratio, age, body weight, the presence of psoriasis and metabolic syndrome were significantly associated with VFA. Conclusion: Psoriasis patients had a higher amount of VFA, compared with the control patients.

1.
van de Kerkhof PCM, Schalkwijk J: Psoriasis; in Bolognia JL, Jorizzo JL, Rapini RP (eds): Dermatology, ed 2. Philadelphia, Mosby Elsevier, 2008, pp 115–135.
2.
Gisondi P, Tessari G, Conti A, et al: Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157:68–73.
3.
Wakkee M, Thio HB, Prens EP, et al: Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007;190:1–9.
4.
Sommer DM, Jenisch S, Suchan M, et al: Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321–328.
5.
Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J: Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008;216:152–155.
6.
Bays HE: ‘Sick fat’, metabolic disease, and atherosclerosis. Am J Med 2009;122:26–37.
7.
Bays HE, González-Campoy JM, Bray GA, et al: Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008;6:343–368.
8.
Després JP: Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006;38:52–63.
9.
Després JP, Lemieux I, Bergeron J, et al: Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008;28:1039–1049.
10.
Kobayashi H, Nakamura T, Miyaoka K, et al: Visceral fat accumulation contributes to insulin resistance, small-sized low-density lipoprotein, and progression of coronary artery disease in middle-aged non-obese Japanese men. Jpn Circ J 2001;65:193–199.
11.
Yamamoto M, Egusa G, Hara H, Yamakido M: Association of intraabdominal fat and carotid atherosclerosis in non-obese middle-aged men with normal glucose tolerance. Int J Obes Relat Metab Disord 1997;21:948–951.
12.
Ashwell M, Cole TJ, Dixon AK: Obesity: new insight into the anthropometric classification of fat distribution shown by computed tomography. Br Med J 1985;290:1692–1694.
13.
Seidell JC, Oosterlee A, Deurenberg P, et al: Abdominal fat depots measured with computed tomography: effects of degree of obesity, sex, and age. Eur J Clin Nutr 1988;42:805–815.
14.
Kvist H, Chowdhury B, Grangård U, et al: Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations. Am J Clin Nutr 1988;48:1351–1361.
15.
Tokunaga K, Matsuzawa Y, Ishikawa K, Tarui S: A novel technique for the determination of body fat by computed tomography. Int J Obes 1983;7:437–445.
16.
Yoshizumi T, Nakamura T, Yamane M, et al: Abdominal fat: standardized technique for measurement at CT. Radiology 1999;211:283–286.
17.
World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Technical Report Series No 727. Geneva, World Health Organization, 1985.
18.
National Institutes of Health: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary. NIH publ. No 01-3670. Bethesda, National Institutes of Health, National Heart, Lung and Blood Institute, 2001.
19.
Naldi L, Chatenoud L, Linder D, et al: Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61–67.
20.
Sterry W, Strober BE, Menter A, International Psoriasis Council: Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007;157:649–655.
21.
Bergman RN, Kim SP, Catalano KJ, et al: Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity (Silver Spring) 2006;14(suppl 1):16–19.
22.
Lafontan M, Berlan M: Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol Sci 2003;24:276–283.
23.
Trayhurn P, Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347–355.
24.
Chen YJ, Wu CY, Shen JL, et al: Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008;144:1571–1575.
25.
Takahashi H, Tsuji H, Takahashi I, et al: Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008;159:1207–1208.
26.
Pajvani UB, Scherer PE: Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep 2003;3:207–213.
27.
Lihn AS, Bruun JM, He G, et al: Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 2004;219:9–15.
28.
Moses AG, Dowidar N, Holloway B, et al: Leptin and its relation to weight loss, ob gene expression and the acute-phase response in surgical patients. Br J Surg 2001;88:588–593.
29.
Sonnenberg GE, Krakower GR, Kissebah AH: A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004;12:180–186.
30.
Setty AR, Curhan G, Choi HK: Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Intern Med 2007;167:1670–1675.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.